Monograph
A06AD65 - Macrogol, Combinations |
Not porphyrinogenic |
NP |
Rationale
Macrogols are not absorbed from the gastrointestinal tract.
Chemical description
Mixtures of polymers.
Therapeutic characteristics
Macrogols are used as osmotic laxatives. A mixture of macrogol 3350 or 4000 with electrolytes is used for bowel preparation before colonoscopy, radiological procedures, or surgery. Common adverse reactions of macrogols that can be confused with an acute porphyric attack are gastrointestinal discomfort, bloating, and nausea.
Metabolism and pharmacokinetics
Not absorbed from the garstrointerstinal tract, eliminated in feces.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Drug reference publications |
| 1. |
Sweetman SC, editor. Martindale: The complete drug reference. Macrogols. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics |
| 2. |
Norwegian medicines agency. Summary of Product Characteristics (SPC). Laxabon.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
